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Abstract
Health-related quality of life instruments are expected to be of particular value in routine care of
people with multiple sclerosis (MS), where they may facilitate the detection of disease aspects that
would otherwise go unrecognised, help clinicians appreciate patient priorities particularly in terms
of treatment goals, facilitate physician-patient communication, and promote shared decision-
making. However, it appears that these instruments are little used routine clinical approaches to
people with MS. To address this issue, I performed a bibliographic search of studies that evaluated
the efficacy of generic or disease-specific health-related quality of life (HRQOL) instruments in MS
clinical practice from clinicians' or patients' perspectives. I found only one cross-sectional study,
which compared preferences for three instruments, and assessed acceptability in people with MS.
Reasons for lack of transfer of HRQOL measurements to clinical practice may be cultural,
methodological, or practical. With regard to MS, the proliferation of instruments seems to
constitute a barrier, with no particular instrument having gained wide popularity or consensus.
Other barriers are lack of resources for the administration, collection and storage of the data, and
inability of clinicians to score, interpret, and use HRQOL instrument to guide clinical care. It is
therefore important to refine existing tools, extending clinical validation to wider contexts and
cultures. More studies assessing acceptability and clinicians' and patients' preferences for different
instruments are also required.
Review
Multiple sclerosis (MS) is a demyelinating disease of the
central nervous system of unknown etiology and poorly
understood pathogenesis. There is a north-south gradient
of MS prevalence in the northern hemisphere, with high-
est levels (over 100 per 100,000) in northern regions
[1,2]. It is a chronic disease with a modest effect on life
expectancy, but a broad spectrum of consequences, of var-
iable severity, on physical and psychological characteris-
tics, that vary between individuals and within individuals
over time. The disease typically strikes women (2:1) in
their peak years of career development and family life;
commonly there are exacerbations and remissions fol-
lowed by progression whose rate and extent vary [3].
There is also a benign form of MS, characterised by few
relapses, long periods of remission, and mild activity lim-
itations over the long term [4]. The available treatments
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have at best a modest benefit on the course of the disease
[5].
Health-related quality of life measures
Interest in measuring outcomes in MS has increased mark-
edly over the past 20 years. Standardised instruments have
been developed, the most-used being the Expanded Disa-
bility Status Scale (EDSS) [6] which is a mixed impair-
ment/activity limitations scale based on neurological
examination of eight functional systems, plus ambula-
tion/mobility status. Despite major limitations – bias
towards locomotor function, variable sensitivity to
change according to scale score, and suboptimal inter-
rater reliability – the EDSS is widely-used by researchers
and clinicians because its scores are readily understood by
all.
More recently, the importance of MS outcome assessment
from the perspective of the person with the disease has
been recognised [7]. After 1992, the number of publica-
tions on health-related quality of life (HRQOL) increased
steadily, as did those employing MS-specific instruments
(see Figure). Generic instruments were applied to MS [7-
12], and disease-specific instruments were devised and
validated [13-24]. The seven available MS-specific
HRQOL instruments are listed in the Table 1; all were
published between 1995 and 2001. Three consist of a
generic module (SF-36 [13,15] or FACT-G [14]) plus an
MS-specific module. In most cases people with MS partic-
ipated in their development [13,16]. Except for the MS
Quality of Life 54 (MSQOL-54), which has been trans-
lated into several languages [13,20-23], and the Func-
tional Assessment of MS (FAMS), which is also available
in Portuguese [24], these questionnaires are available only
their original versions. Aspects of responsiveness were
evaluated in four of the seven instruments, but in general
sensitivity to change has been insufficiently investigated
[18,25-28]
HRQOL and routine clinical practice
HRQOL studies in MS have drawn attention to the multi-
plicity of domains that may be compromised by the dis-
ease, and the effects of this compromise on ability to cope.
As expected, people with MS, especially those with a pro-
gressive course, report reduced physical functioning com-
pared to the general population [10,11,29-31]; they are
more likely to suffer fatigue [29,32] and depression
[32,33] than the general population, and are also more
likely to be unemployed [8,10,30,31,34,35]. Unexpect-
edly, however, it has been reported that the importance
attached to compromise in different HRQOL domains
may vary considerably between MS sufferers and their
neurologists [7].
The ultimate aim of measuring HRQOL is to provide a
comprehensive assessment of patients' health status, to
serve as a baseline from which to tailor interventions,
pharmacological or otherwise, and assess their effective-
ness, both in the clinical trial setting and in routine care.
HRQOL instruments are expected to be of particular value
Table 1: Characteristics of MS-specific HRQOL questionnaires
MSQOL-54 FAMS MSQLI RAYS HAQUAMS MSIS-29 LMSQoL
Publication year 1995 1996 1999 2000 2001 2001 2001
Generic module SF-36 (36 items) FACT-G (28 items) SF-36 (36 items) -- -- -- --
MS module 18 items 31 items 9 scales 50 items 38 items 29 items 8 items
People with MS 
involved in 
development
No Yes -- No MYes Yes Yes
Versions US English [13]
Italian [20]
French [21]
Canadian French [22]
Japanese [23]
US English [14]
Portuguese [24]
US English [15] Hebrew [16] German [17] English [18] English [19]
Reliability Alpha Test-retest 
[13,20–23]
Alpha [14,24] Alpha Test-retest 
[15]
Alpha [16] Alpha Test-retest 
[17]
Alpha Test-retest 
[18]
Alpha Test-retest 
[19]
Responsiveness RCT [25]
RCT [26]
-- RCT [27] -- RCT [28] Effect size [18] --
Domains not 
assessed
Vision Vision
Bladder/ bowel
Sexual function
-- -- -- Vision
Sexual function
Vision
Time period 
assessed
Past 4 weeks
Current time
Past week -- Past week Past year
Past 4 weeks
Past week
Past 2 weeks Past month
Time to complete 20 minutes 20 minutes -- -- 20 minutes -- --
Publications (no.) 16 10 5 1 3 7 2
Publication period 1995–2004 1996–2004 1999–2003 2000 2001–2004 2001–2004 2001
MSQOL-54 is the MS quality-of-life 54; FAMS is the Functional Assessment of MS; MSQLI is the MS Quality of Life; HAQUAMS is the Hamburg 
Quality of Life Questionnaire in MS; FACT-G is the Functional Assessment of Cancer Therapy, General version; LMSQoL is the Leeds MS Quality of 
Life. Alpha is Cronbach's coefficient alpha. RCT aspects of responsiveness assessed in randomized controlled trial.Health and Quality of Life Outcomes 2005, 3:16 http://www.hqlo.com/content/3/1/16
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in routine care, where they may improve the detection of
disease aspects that would otherwise go unrecognised,
help clinicians appreciate patient priorities particularly in
terms of treatment goals, facilitate physician-patient com-
munication, and promote shared decision making. In
addition HRQOL data from clinical trials can provide
information that clinicians can usefully discuss with their
patients [36]. Unfortunately, although recent MS trials
include some HRQOL assessment, there is no internation-
ally agreed gold standard for conducting such assessment
or reporting outcomes. HRQOL evaluations are not
required as endpoints in MS trials by the European Agency
for the Evaluation of Medicinal Products [37]. Even when
HRQOL endpoints are included, data collection and
reporting are often of poor quality [38] with the conse-
quence that cost effectiveness issues, which HRQOL
instruments can throw light on, such as preserved func-
tion, less work missed, and improved emotional well-
being, are not analysed.
Literature survey
It appears that HRQOL instruments are little used in rou-
tine clinical approaches to people with MS. To address
this issue, I searched MEDLINE (1966–2004), the
Cochrane Library (Issue 1, 2005) and the Cochrane MS
Group trials register (2004) for studies that evaluated the
efficacy of generic or MS-specific HRQOL instruments in
clinical practice from the clinicians' or MS patients' per-
spective, also checking study references. Studies consider-
ing patient-reported outcomes other than HRQOL, and
domain-specific measures were excluded.
I found only one study, a cross-sectional postal survey
conducted in Canada, published in 2004 [39]. This study
assessed MS sufferers' preferences regarding two generic
instruments (the EuroQol EQ-5D and the SF-36), and an
MS-specific instrument (MSQOL-54). Over 90% of 183
participants reported that EuroQol EQ-5D and the SF-36
were acceptable or very acceptable, and 85% did so for
MSQOL-54. Surprisingly, over 75% of participants felt
that a combination of the three instruments best
described their HRQOL.
The reasons for lack of transfer of HRQOL assessment into
clinical practice may be cultural, practical, or methodolog-
ical [40-43]. With regard to cultural factors, patients gen-
erally welcome the opportunity to provide clinicians with
information regarding their HRQOL [43]. That this is also
the case for people with MS is suggested by high participa-
tion rates in most postal surveys assessing patient-
reported health status [30,35,39,44], and by the good
acceptability of HRQOL instruments [39]. By contrast,
information on practicing clinicians' perceptions of the
utility of HRQOL data is limited and conflicting: studies
have uncovered a lack of knowledge of HRQOL as well as
concerns that these instruments may be a covert means of
assessing physicians' performance [45,46].
Practical considerations be particularly important in clin-
ical settings, where data must be provided promptly and
in an understandable manner to be of use. Instruments
must be administered, processed, scored, stored and
retrieved – all of which have logistic and financial impli-
cations [47]. Most HRQOL instruments are lengthy and
may be burdensome for patients and clinicians. For most
existing instruments, the score is not immediately availa-
ble, but needs to be calculated, while score interpretation
may not be straightforward. For example a recently pub-
lished study on transplant physicians found that 55%
would be more likely to use HRQOL data if it were more
comprehensible [48]. In the United States time spent
gathering and interpreting HRQOL information as part of
the clinical encounter is not built into reimbursement by
third-party payers [49]. It is noteworthy, however, that
questionnaire length seems not to be a drawback for peo-
ple with MS since a combination of HRQOL instruments
was preferred by over 75% of participants in the only
study found [39].
Another factor limiting the dissemination of HRQOL
tools in MS clinical practice is likely to be that too many
instruments are available, and unlike EDSS, none has
emerged as clearly superior to any other.
Number of publications on HRQOL in people with MS  between 1992 and 2004 Figure 1
Number of publications on HRQOL in people with MS 
between 1992 and 2004. Blue bars indicate all studies on 
HRQOL; light blue bars indicate studies employing MS-spe-
cific instruments. Studies considering patient-reported out-
comes other than HRQOL, or domain-specific measures are 
excluded.
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Conclusion
Existing HRQOL tools for people with MS should be
refined and their clinical validation pursued in the widest
possible cultural context. More studies assessing instru-
ment acceptability and preferences of clinicians and
people with MS are also needed. It would be useful for
example to implement computer-based technology
(touch-screens and adaptive administration to reduce
respondent burden by selecting pertinent items and omit-
ting inappropriate ones) and other alternatives to tradi-
tional paper-and-pencil or interview methods, which
should of course be evaluated for acceptability and relia-
bility [48]. The objective is not to add HRQOL measure-
ments to the chores of everyday practice, but to
incorporate meaningful HRQOL instruments into the care
process [50].
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